(Q37940162)

English

Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.

scientific article published on 29 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Andrew D Smith

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Shetal N Shah

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Brian I Rini

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Michael L Lieber

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

29 September 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Urologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1283-1291

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

We should desist using RECIST, at least in GIST.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.010

7 January 2021

Identifiers

10.1016/J.UROLONC.2011.08.010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

release_ifo7o6cq7jgtbadhq5taqhguau

1 reference

https://api.fatcat.wiki/v0/release/ifo7o6cq7jgtbadhq5taqhguau

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21956044%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37940162&oldid=2097634704"